Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

New Technologies Help Hospitals Tackle Patient Safety Push

Executive Summary

CMS continues to tighten its rules on so-called "never events" - conditions acquired during hospitalization - in an ongoing effort to slash Medicare costs and improve care for hospitalized patients. And the HAC rules currently in place have already provided significant impetus for hospitals to take steps to improve the identification and prevention of nosocomial infections. Nowa growing group of companies with innovative new technologies aim to capitalize on this trend by helping hospitals take their efforts even further.

You may also be interested in...



Automated Patient Surveillance Systems Take Aim at Hospital Infection Control Practice

Pressure to adopt the latest infection control solutions will continue to grow as payor reimbursement becomes more closely tied to how hospitals perform in the area of health care associated infections. Automated patient surveillance systems offer health care facilities the ability to identify pathogen patterns and identify when control limits have been reached. This may help health care professionals slow or even completely prevent outbreaks, representing a significant improvement over conventional methods of tracking infections.

Diabetes: CGM Goes Mainstream

Getting a breakthrough medical device from the drawing board into mainstream use is the primary goal of every manufacturer, but a variety of factors influences how quickly a device reaches that goal - if at all. Right now, that process is playing out in the diabetes market, where continuous glucose monitoring (CGM) is moving closer to becoming a staple of effective diabetes treatment. The three companies that produce CGM devices - Medtronic, DexCom, and Abbott Laboratories - are very active in demonstrating the value of this technology, but other companies are stepping up in the market. Meanwhile, the focus on CGM is having an effect on other products, including insulin pumps.

Diabetes: CGM Goes Mainstream

Getting a breakthrough medical device from the drawing board into mainstream use is the primary goal of every manufacturer, but a variety of factors influences how quickly a device reaches that goal - if at all. Right now, that process is playing out in the diabetes market, where continuous glucose monitoring (CGM) is moving closer to becoming a staple of effective diabetes treatment. The three companies that produce CGM devices - Medtronic, DexCom, and Abbott Laboratories - are very active in demonstrating the value of this technology, but other companies are stepping up in the market. Meanwhile, the focus on CGM is having an effect on other products, including insulin pumps.

Related Content

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT035196

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel